Publication Name	World Journal of Hepatology
Manuscript ID	16359
Country	China

Received	2015-01-13 17:18
Peer-Review Started	2015-01-15 23:13
To Make the First Decision	2015-02-07 14:50
Return for Revision	2015-02-10 08:56
Revised	2015-02-14 16:34
Second Decision	2015-02-27 09:46
Accepted by Journal Editor-in-Chief	2015-02-27 16:33
Accepted by Executive Editor-in-Chief	2015-03-09 17:37
Articles in Press	2015-03-09 17:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-16 10:53
Publish the Manuscript Online	2015-05-01 19:01

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification
Manuscript Source	Invited Manuscript
All Author List	Wai-Kay Seto
Funding Agency and Grant Number
Corresponding Author	Dr. Wai-Kay Seto, Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. wkseto@hku.hk
Key Words	Hepatitis B virus; Antibody to hepatitis B core antigen; Hepatitis B surface antigen; Rituximab; Antigen CD20; Hematopoietic stem cell transplantation; Antibody to tumor necrosis factor; Occult
Core Tip	Hepatitis B virus (HBV) reactivation not only occurs in hepatitis B surface antigen (HBsAg)-positive, but also in HBsAg-negative, antibody to hepatitis B core antigen positive individuals. Immunosuppressive therapies with increased risk of HBV reactivation include corticosteroids, anthracyclines, rituximab, antibody to tumor necrosis factor and hematopoietic stem cell transplantation. The decision between prophylactic antiviral therapy vs routine clinical monitoring would involve appropriate risk stratification for individual types of immunosuppressives regimes.
Publish Date	2015-05-01 19:01
Citation	Seto WK. Hepatitis B virus reactivation during immuno­suppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830
URL	http://www.wjgnet.com/1948-5182/full/v7/i6/825.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i6.825

Full Article (PDF)	WJH-7-825.pdf
Full Article (Word)	WJH-7-825.doc
Manuscript File	16359-Review.docx
Answering Reviewers	16359-Answering reviewers.pdf
Audio Core Tip	16359-Audio core tip.wav
Conflict-of-Interest Disclosure Form	16359-Conflict-of-interest statement.pdf
Copyright License Agreement	16359-Copyright assignment.pdf
Peer-review Report	16359-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	16359-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	16359-Scientific misconduct check.pdf
Scientific Editor Work List	16359-Scientific editor work list.pdf